Therapy insight: Management of hepatorenal syndrome

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 6, 2006, Pages 338-348

  Cárdenas, Andrés ^a   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ascites; Cirrhosis; Dilutional hyponatremia; Portal hypertension

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); MIDODRINE; MISOPROSTOL; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PENTOXIFYLLINE; PLACEBO; PLASMA SUBSTITUTE; SODIUM; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ABDOMINAL CRAMP; ACUTE DISEASE; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ARTERIAL CIRCULATION; BACTERIAL PERITONITIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DIARRHEA; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; HYPOKINESIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MYOCARDIAL DISEASE; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM RETENTION; SODIUM URINE LEVEL; SPLANCHNIC BLOOD FLOW; SURVIVAL; TREATMENT PLANNING; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC ALPHA-AGONISTS; HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS;

EID: 33744918285     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0517     Document Type: Review

References (67)

1. Arroyo V et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164-176
2. Ginès P et al. (2004) Management of cirrhosis and ascites. N Engl J Med 350: 1646-1654
3. Akriviadis E et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 119: 1637-1648
4. Moore K (1999) Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 11: 967-975
5. Gines A et al. (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105: 229-236
6. Alessandria C et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology 41: 1282-1289
7. Sort P et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 5: 403-409
8. Epstein M et al. (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49: 175-185
9. Schrier RW et al. (1988) Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157
10. Iwakiri Y and Groszmann R (2006) The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 43 (Suppl 1): S121-S131
11. Bernardi M and Domenicali M (2005) The reninangiotensin-aldosterone system in cirrhosis. In Ascites and renal dysfunction in liver disease, 43-53 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
12. Dudley F and Esler M (2005) The sympathetic nervous system in cirrhosis. In Ascites and renal dysfunction in liver disease, 54-72 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
13. Ishikawa S and Schrier RW (2003) Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58: 1-17
14. Arroyo V and Colmenero J (2003) Ascites and hepatorenal syndrome in cirrhosis: Pathophysiological basis of therapy and current management. J Hepatol 38 (Suppl 1): S69-S89
15. Terra C et al. (2005) Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 129: 1944-1953
16. Ruiz-del-Arbol L et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42: 439-447
17. Ruiz-del-Arbol W et al. (2003) Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38: 1210-1218
18. Lenz K (2005) Hepatorenal syndrome-is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 42: 263-265
19. Cärdenas A and Ginès P (2005) Management of hyponatremia in cirrhosis. In Ascites and renal dysfunction in liver disease, 305-314 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
20. Caregaro L et al. (1994) Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154: 201-205
21. Sherman D et al. (2003) Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41: 269-278
22. Cärdenas A (2005) Hepatorenal syndrome: A dreaded complication of end-stage liver disease. Am J Gastroenterology 100: 1-8
23. Ginès P et al. (1998) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493-1502
24. Follo A et al. (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495-1501
25. Angeli P et al. (2006) Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: Similar efficacy at lower cost. Aliment Pharmacol Ther 23: 75-84
26. Cärdenas A et al. (2001) Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology 34: 671-676
27. Guevara M et al. (2004) Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology 40: 646-651
28. Watt K et al. (2002) Hepatorenal syndrome: Diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 97: 2046-2050
29. Servin-Abad L et al. (2005) Retrospective analysis of 140 patients labeled as hepatorenal syndrome in a referral center [abstract]. Hepatology 42: 543A
30. Fernandez J et al. (2005) A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627-634
31. Rimola A et al. (2005) Liver transplantation for patients with cirrhosis and ascites. In Ascites and renal dysfunction in liver disease, 271-285 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
32. Cärdenas A and Ginès P (2005) Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 42 (Suppl 1): S124-S133
33. Restuccia T et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 40: 140-146
34. Testino G et al. (2003) Type-2 hepatorenal syndrome and refractory ascites: Role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50: 1753-1755
35. Brensing KA et al. (2000) Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 47: 288-295
36. Alessandria C et al. (2002) Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14: 1363-1368
37. Arroyo V et al. (2005) Hepatorenal syndrome in cirrhosis: Clinical features, diagnosis, and management. In Ascites and renal dysfunction in liver disease, 341-359 (Eds Ginès P et al.) Oxford, UK: Blackwell Publishing
38. Angeli P et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690-1697
39. Fevery J et al. (1990) Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 11: 153-158
40. Gines A et al. (1993) Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 17: 220-226
41. Soper CP et al. (1996) Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 347: 1842-1843
42. Holt S et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353: 294-295
43. Guevara M et al. (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27: 35-41
44. Gulberg V et al. (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30: 870-875
45. Hadengue A et al. (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29: 565-570
46. Uriz J et al. (2000) Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 33: 43-48
47. Moreau R et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 122: 923-930
48. Ortega R et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 36: 41-48
49. Mulkay JP et al. (2001) Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 64: 15-19
50. Halimi C et al. (2002) Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153-158
51. Colle I et al. (2002) Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: A retrospective analysis. J Gastroenterol Hepatol 17: 882-888
52. Solanki P et al. (2003) Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152-156
53. Saner F et al. (2004) Terlipressin and gelafundin: Safe therapy of hepatorenal syndrome. Eur J Med Res 9: 78-82
54. Saner FH et al. (2003) Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gastroenterol Hepatol 15: 925-927
55. Gluud LL et al. (2005) Terlipressin for hepatorenal syndrome. The Cochrane Database of Systematic Reviews J Hepatol 42 (Suppl 2): 81
56. Wong F et al. (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55-64
57. Duvoux C et al. (2002) Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: A pilot study. Hepatology 36: 374-380
58. Arroyo V et al. (2005) Circulatory dysfunction in cirrhosis. In Update in Treatment of Liver Disease, 19-28 (Eds Arroyo V et al.) Barcelona: Ars Medica
59. Pomier-Layrargues G et al. (2003) Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study. Hepatology 38: 238-243
60. Boyer TD and Haskal Z (2005) The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41: 386-400
61. Guevara M et al. (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 28: 416-422
62. D'Amico G et al. (2005) Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis. Gastroenterology 129: 1282-1293
63. Albillos A et al. (2005) A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 43: 990-996
64. Kapling RK and Bastani B (2004) The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 26: 563-568
65. Keller F et al. (1995) Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): The role of hemodialysis. Ren Fail 17: 135-146
66. Mitzer SR et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277-286
67. Rifai K et al. (2005) The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23: 298-302